Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA

Administration of C1-esterase inhibitor (C1-INH) attenuates myocardial necrosis and sustains normal cardiac performance after myocardial ischemia and re-perfusion in animal experiments. We report on our first experience of C1-INH application as rescue therapy in patients undergoing emergency surgica...

Full description

Saved in:
Bibliographic Details
Main Authors: Bauernschmitt, Robert (Author) , Hagl, Siegfried (Author) , Böhrer, Hubert (Author)
Format: Article (Journal)
Language:English
Published: June 1998
In: Intensive care medicine
Year: 1998, Volume: 24, Issue: 6, Pages: 635-638
ISSN:1432-1238
DOI:10.1007/s001340050629
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s001340050629
Get full text
Author Notes:R. Bauernschmitt, S. Hagl, H. Böhrer
Description
Summary:Administration of C1-esterase inhibitor (C1-INH) attenuates myocardial necrosis and sustains normal cardiac performance after myocardial ischemia and re-perfusion in animal experiments. We report on our first experience of C1-INH application as rescue therapy in patients undergoing emergency surgical revascularization after failed percutaneous transluminal coronary angioplasty. Three patients were treated, because postoperative hemodynamic stabilization could not be achieved despite prolonged reperfusion periods, high-dose inotropic support, inodilators and aortic counterpulsation. As there was no surgical or medical option remaining, C1-INH was administered starting with a 2000 unit bolus, followed by 1000 U 12 and 24 h after surgery. C1-INH therapy resulted in rapid hemodynamic stabilization of all patients; weaning from aortic counterpulsation and epinephrine support was possible within 1 day. All patients survived and were discharged from hospital. In this group of patients suffering from severe reperfusion injury after coronary surgery, C1-INH seemed to be an effective adjuvant therapy to restore myocardial function by blocking the complement cascade. These results should encourage the performance of controlled studies on the effects of prophylactic C1-INH substitution therapy in patients undergoing coronary surgery at high risk conditions.
Item Description:Gesehen am 11.06.2025
Physical Description:Online Resource
ISSN:1432-1238
DOI:10.1007/s001340050629